On October 9, JOINN fell 5.59% in regular trading, with the stock trading at HKD 28.44 and turnover of HKD 21.35 million.

The decline was driven by broad-based selling pressure across the Hong Kong pharmaceutical and CRO sector. Market sentiment was dampened by a sharp sell-off in U.S. pharmaceutical stocks overnight, after Citigroup downgraded Moderna to Sell and slashed its target price, sparking a cross-market transmission of negative sentiment that dragged down CRO and innovative drug names including WuXi Bio, WuXi XDC, Insilico Medicine, and WuXi AppTec.

Despite JOINN's solid fundamentals, with first-half new orders up 98% year-on-year and Morgan Stanley recently increasing its H-share stake, the short-term sector-wide deleveraging continued to dominate trading.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)